HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Roque Pifarré Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Najman, D. M. Articles by Pifarré, R. Search for Related Content PubMed PubMed Citation Articles by Najman, D. M. Articles by Pifarré, R.

Ann Thorac Surg 1993;55:662-666
© 1993 The Society of Thoracic Surgeons

---

Articles

Effects of aprotinin on anticoagulant monitoring: Implications in cardiovascular surgery

Departments of Pathology and Thoracic and Cardiovascular Surgery, Loyola University Medical Center, Maywood, Illinois, USA

Accepted for publication June 29, 1992.

^_* Address reprint requests to Dr Walenga, Department of Pathology, Loyola University Medical Center, 2160 S First Ave, Maywood, IL 60153.

This study was designed to evaluate anticoagulant monitoring of heparin and platelet function in the presence of aprotinin. Aprotinin added to heparinized whole blood at concentrations equal to (30 µg/mL), twice, and four times that used in cardiopulmonary bypass operations synergistically elevated the activated clotting time (ACT) (536 ± 73, 651 ± 86, and 787 ± 71 seconds, respectively) over the value with heparin alone (384 ± 66 seconds) (p < 0.001). In addition, the ACT of heparin-aprotinin mixtures supplemented with protamine showed that the heparin was not completely neutralized (131 ± 12 versus 98 ± 7 seconds). Specific tests revealed that the effect on ACT caused by aprotinin is not equal to the anticoagulant effect of heparin. Thus there is a risk of underheparinization if the ACT is used as a monitor when aprotinin is present. Furthermore, protamine doses relative to the heparin concentration, and not relative to the ACT, should be used to reverse heparin. In studying the effects of aprotinin on platelet function, there was a significant inhibition of aggregation when normal platelets were supplemented with aprotinin, but not for platelets of postoperative patients. This suggests that aprotinin may interact more favorably with nonactivated platelet surfaces, reducing or inhibiting the expression of receptors. Thus it is necessary to treat a patient with aprotinin before beginning cardiopulmonary bypass. Based on these data, the effect of aprotinin on the hemostatic system and its drug interactions must be considered to optimize safety and efficacy during cardiopulmonary bypass operations.

This article has been cited by other articles:

				M. Wallock, W. P Jeske, M. Bakhos, and J. M Walenga Evaluation of a new point of care heparin test for cardiopulmonary bypass: the TAS heparin management test Perfusion, March 1, 2001; 16(2): 147 - 153. [Abstract] [PDF]

				R. Pifarre Use of Aprotinin in the Control of Bleeding During Cardiopulmonary Bypass Surgery: Current Status Clinical and Applied Thrombosis/Hemostasis, January 1, 1998; 4(1): 2 - 6. [Abstract] [PDF]

				N. Hayashida, T. Isomura, T. Sato, H. Maruyama, K. Kosuga, and S. Aoyagi EFFECTS OF MINIMAL-DOSE APROTININ ON CORONARY ARTERY BYPASS GRAFTING J. Thorac. Cardiovasc. Surg., August 1, 1997; 114(2): 261 - 269. [Abstract] [Full Text]

				M. R. Terrell, J. M. Walenga, M. J. Koza, and R. Pifarre Efficacy of Aprotinin With Various Anticoagulant Agents in Cardiopulmonary Bypass Ann. Thorac. Surg., August 1, 1996; 62(2): 506 - 511. [Abstract] [Full Text]

				J. H. Levy, R. Pifarre, H. V. Schaff, J. C. Horrow, R. Albus, B. Spiess, T. K. Rosengart, J. Murray, R. E. Clark, P. Smith, et al. A Multicenter, Double-Blind, Placebo-Controlled Trial of Aprotinin for Reducing Blood Loss and the Requirement for Donor-Blood Transfusion in Patients Undergoing Repeat Coronary Artery Bypass Grafting Circulation, October 15, 1995; 92(8): 2236 - 2244. [Abstract] [Full Text]

				R. Pifarre State-of-the-Art Review: Optimal Anticoagulation in Cardiovascular Surgery Clinical and Applied Thrombosis/Hemostasis, June 1, 1995; 1(3): 173 - 178. [Abstract] [PDF]

				N. Tabuchi, T. L. Njo, I. Tigchelaar, R. J. Huyzen, P. W. Boonstra, and W. van Oeveren Monitoring of anticoagulation in aprotinin-treated patients during heart operation Ann. Thorac. Surg., September 1, 1994; 58(3): 774 - 777. [Abstract] [PDF]

				C. R. Smith, L. B. Mongero, C. M. DeRosa, R. E. Michler, and M. C. Oz Safety of aprotinin in profound hypothermia and circulatory arrest Ann. Thorac. Surg., August 1, 1994; 58(2): 606 - 607. [PDF]

				T. A. Alston and M. N. D'Ambra Aprotinin does not neutralize heparin Ann. Thorac. Surg., February 1, 1994; 57(2): 516 - 516. [PDF]

				J. H. Lemmer Jr., W. Stanford, S. L. Bonney, J. F. Breen, E. V. Chomka, W. J. Eldredge, W. W. Holt, R. B. Karp, G. W. Laub, M. J. Lipton, et al. Aprotinin for coronary bypass operations: Efficacy, safety, and influence on early saphenous vein graft patencyA multicenter, randomized, double-blind, placebo-controlled study J. Thorac. Cardiovasc. Surg., February 1, 1994; 107(2): 543 - 553. [Abstract] [Full Text]